Positive T-Track® CMV Study Results With New Guidance Strategies For Anti-viral Treatment Decisions Following Stem Cell Transplantation

Continued Validation of Lophius’ Development Capabilities Bode Well as Company Advances in Tuberculosis as Next Focus Area

Read more

January 08, 2019 - Lophius Biosciences establishes Social Media Channels

Lophius is now on LinkedIn and Twitter. Read the “Letter from our CEO” to learn more about our mission and vision in tuberculosis and other life-threatening infectious diseases.

Read more

February 08, 2018 – T-Track® CMV is a Highly Sensitive Immune-Monitoring Tool for Risk Stratification of Renal Transplant Recipients

A new peer-reviewed scientific publication covers T-Track® CMV in a clinical study with kidney transplant patients.

Read more

September 27, 2017 - Lophius and Mediphos sign exclusive distribution partnership for T-Track® CMV in the Benelux countries

Lophius Biosciences GmbH and Mediphos Medical Supplies B.V. today announced their distribution partnership for the in vitro diagnostic test T-Track® CMV.

Read more

September 1, 2017 - Launch of the Next Generation T-Track® CMV Immune Monitoring Tool

Today Lophius Biosciences launched the next generation of its in vitro diagnostic test T-Track® CMV for the risk stratification of human cytomegalovirus (CMV)-related clinical complications in transplant recipients.

Read more

May 31, 2017 – Lophius Biosciences Receives Public Grant for the Development of an Advanced Diagnostic Tuberculosis Test

Lophius Biosciences GmbH today announced that it has been awarded a public grant funding of 0.65 MEUR from the German Federal Ministry of Education and Research to develop a blood based diagnostic test for the rapid and efficient diagnosis of tuberculosis.

Read more
This function requires IE9 or higher.
You can update your browser under:
http://windows.microsoft.com/de-DE/internet-explorer/download-ie